Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 483-491

  Wachsberger, Phyllis R ^a   Lawrence, Yaacov R ^a   Liu, Yi ^a   Daroczi, Borbala ^a   Xu, Xia ^b   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cediranib; Glioblastoma; Radiotherapy; Vandetanib; wtEGFR

Indexed keywords

ANTI-TUMOR EFFICACY; ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORS; CEDIRANIB; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR RECEPTORS; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMAS; GROWTH FACTOR; IN-VITRO; IN-VIVO; MICROENVIRONMENTAL EFFECTS; OVER-EXPRESSION; SURVIVIN; TUMOR DOUBLING TIME; TUMOR GROWTH; TUMOR SAMPLES; TYROSINE KINASE INHIBITOR; VANDETANIB; VEGF RELEASE; WILD TYPES; WTEGFR;

AMINO ACIDS; BIOACTIVITY; CELLS; ENZYMES; PEPTIDES; RADIOTHERAPY; TUMORS;

GROWTH KINETICS;

CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN KINASE B; SURVIVIN; VANDETANIB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RADIATION RESPONSE; RADIOSENSITIVITY; STAINING; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DRUG ADMINISTRATION SCHEDULE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; PIPERIDINES; QUINAZOLINES; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83955164321     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.09.019     Document Type: Article

References (29)

1. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
2. J.S. Smith, I. Tachibana, S.M. Passe, B.K. Huntley, T.J. Borell, and N. Iturria PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme J Natl Cancer Inst 93 2001 1246 1256
3. A. Chakravarti, A. Chakladar, M.A. Delaney, D.E. Latham, and J.S. Loeffler The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62 2002 4307 4315
4. C.A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, and S. Yla-Herttuala The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis Cancer Res 68 2008 4754 4762
5. W.S. Kamoun, C.D. Ley, C.T. Farrar, A.M. Duyverman, J. Lahdenranta, and D.A. Lacorre Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 2009 2542 2552
6. S.R. Wedge, J. Kendrew, L.F. Hennequin, P.J. Valentine, S.T. Barry, and S.R. Brave AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 2005 4389 4400
7. T.T. Batchelor, D.G. Duda, E. di Tomaso, M. Ancukiewicz, S.R. Plotkin, and E. Gerstner Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 17 2010 2817 2823
8. W.D. Brazelle, W. Shi, and D.W. Siemann VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy Int J Radiat Oncol Biol Phys 65 2006 836 841
9. C. Cao, J.M. Albert, L. Geng, P.S. Ivy, A. Sandler, and D.H. Johnson Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer Cancer Res 66 2006 11409 11415
10. V. Damiano, D. Melisi, C. Bianco, D. Raben, R. Caputo, and G. Fontanini Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma Clin Cancer Res 11 2005 5639 5644
11. B. Frederick, D. Gustafson, C. Bianco, F. Ciardiello, I. Dimery, and D. Raben ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy Int J Radiat Oncol Biol Phys 64 2006 33 37
12. K. Shibuya, R. Komaki, T. Shintani, S. Itasaka, A. Ryan, and J.M. Jurgensmeier Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer Int J Radiat Oncol Biol Phys 69 2007 1534 1543
13. K.J. Williams, B.A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I.J. Stratford, and S.R. Wedge ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
14. M.Y. Wang, K.V. Lu, S. Zhu, E.Q. Dia, I. Vivanco, and G.M. Shackleford Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells Cancer Res 66 2006 7864 7869
15. W.K. Sinclair, and R.A. Morton X-ray and ultraviolet sensitivity of synchronized Chinese hamster cells at various stages of the cell cycle Biophys J 5 1965 1 25
16. P. Wachsberger, R. Burd, A. Ryan, C. Daskalakis, and A.P. Dicker Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model Int J Radiat Oncol Biol Phys 75 2009 854 861
17. P.R. Wachsberger, R. Burd, N. Marero, C. Daskalakis, A. Ryan, P. McCue, and A.P. Dicker Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma Clin Cancer Res 11 2005 835 842
18. P.R. Wachsberger, R. Burd, C. Cardi, M. Thakur, C. Daskalakis, J. Holash, and G.D. Yancopoulos VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma Int J Radiat Oncol Biol Phys 67 2007 1526 1537
19. K.J. Williams, B.A. Telfer, A.M. Shannon, M. Babur, I.J. Stratford, and S.R. Wedge Inhibition of vascular endothelial growth factor signalling using cediranib (Recentin; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts Br J Radiol 81 Spec. no 1 2008 S21 S27
20. D.L. Gustafson, B. Frederick, A.L. Merz, and D. Raben Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts Cancer Chemother Pharmacol 61 2008 179 188
21. P. Knizetova, J. Ehrmann, A. Hlobilkova, I. Vancova, O. Kalita, Z. Kolar, and J. Bartek Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay Cell Cycle 7 2008 2553 2561
22. S.J. Kim, H. Uehara, T. Karashima, D.L. Shepherd, J.J. Killion, and I.J. Fidler Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 2003 1200 1210
23. P. Dent, D.B. Reardon, J.S. Park, G. Bowers, C. Logsdon, K. Valerie, and R. Schmidt-Ullrich Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death Mol Biol Cell 10 1999 2493 2506
24. P. Kumar, A.I. Miller, and P.J. Polverini p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway J Biol Chem 279 2004 43352 43360
25. S. Lanza-Jacoby, A.P. Dicker, S. Miller, F.E. Rosato, J.T. Flynn, S.N. Lavorgna, and R. Burd Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice Mol Cancer Ther 3 2004 417 424
26. P. Wachsberger, R. Burd, and A.P. Dicker Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways Hematol Oncol Clin North Am 18 2004 1039 1057
27. J. Tran, Z. Master, J.L. Yu, J. Rak, D.J. Dumont, and R.S. Kerbel A role for surviving in chemoresistance of endothelial cells mediated by VEGF Proc Natl Acad Sci U S A 99 2002 4349 4354
28. T.T. Batchelor, A.G. Sorensen, E. di Tomaso, W.T. Zhang, D.G. Duda, and K.S. Cohen AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95
29. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740